ANTUREC's mission embraces research and development in the area of new targeted recombinant drugs against cancer and the translation of promising compounds from the laboratory to the clinic. ANTURECs first ANti TUmor RECombinant pharmaceutical – the Investigational Medicinal Product (IMP) tTF-NGR – is in clinical phase III studies in oncology. In addition to the clinical lead structure tTF-NGR, ANTUREC follows active preclinical programs on other targeted proteins.